HIMALAYA: Patient-Reported Outcomes for Patients With Unresectable Hepatocellular Carcinoma Receiving Durvalumab ± Tremelimumab

Source: 2022 ASCO Annual Meeting*
Download Slideset
June 3-7, 2022; Chicago, Illinois
Compared with sorafenib treatment alone, addition of a single dose of tremelimumab to durvalumab in STRIDE and durvalumab monotherapy were associated with meaningful, patient-centered benefits for patients with unresectable hepatocellular carcinoma.
Format: Microsoft PowerPoint (.ppt)
File Size: 132 KB
Released: June 6, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Bristol-Myers Squibb
Daiichi Sankyo, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings